Bulk Pharmaceutical API Sources for GLEOSTINE

Bulk Pharmaceutical API Sources for GLEOSTINE

Vendor	Vendor Homepage	Vendor Sku	API Url
Molport		MolPort-001-768-818
Oakwood Products		036500
Amadis Chemical		A806019
AKos Consulting & Solutions		AKOS005766022
TCI (Tokyo Chemical Industry)		L0251

Bulk Active Pharmaceutical Ingredient (API) Sources for GLEOSTINE (Procarbazine HCl)

Last updated: July 29, 2025

---

Introduction

Gleostine (generic name: procarbazine hydrochloride) is a chemotherapeutic agent primarily utilized in the treatment of Hodgkin’s lymphoma, brain tumors, and other malignancies. As with many cancer drugs, access to high-quality bulk APIs is essential for pharmaceutical manufacturing, ensuring drug efficacy, safety, and compliance with regulatory standards. This article provides a comprehensive overview of global suppliers and sources of procarbazine HCl (API), focusing on supply chain dynamics, manufacturing capabilities, and regulatory considerations.

---

Overview of Procarbazine API

Procarbazine hydrochloride is a formaldehyde-methylhydrazine derivative with specific pharmacological properties. Its production involves complex synthetic pathways, often requiring rigorous quality control. The API’s characteristics necessitate sourcing from suppliers adhering to Good Manufacturing Practices (GMP), ensuring pharmaceutical-grade quality suitable for formulation.

---

Global API Manufacturers and Suppliers

1. Major API Manufacturers

Several global pharmaceutical companies produce procarbazine API, primarily located in regions with well-established pharmaceutical industries such as Europe, North America, and Asia. They typically supply to branded and generic drug manufacturers worldwide.

• Apotex Inc. (Canada)
  Apotex is known for manufacturing a broad spectrum of generic APIs, including chemotherapeutic agents. Their facilities maintain GMP compliance, enabling supply of APIs for export and domestic use. Apotex's testing and validation ensure the API meets pharmacopeial standards such as USP, EP, or JP.

• Sun Pharmaceutical Industries Ltd. (India)
  One of the largest generic pharmaceutical players globally, Sun Pharma manufactures various APIs, including niche chemotherapeutics. Their integrated manufacturing facilities incorporate advanced synthetic processes and quality assurance frameworks, making them a significant source for high-quality APIs.

• Fresenius Kabi (Germany)
  A leading producer of injectable drugs and APIs, Fresenius Kabi maintains stringent GMP standards. Although primarily focused on large-volume injectables, their API manufacturing for chemotherapeutics like procarbazine ensures adherence to international quality standards.

• Nanjing Pharma (China)
  China’s pharmaceutical industry has expanded rapidly, with numerous companies capable of producing chemotherapeutic APIs. Nanjing Pharma stands out for its commitment to GMP compliance and competitive pricing, serving both domestic and export markets.

• Aurobindo Pharma (India)
  Known for cost-effective manufacturing of complex APIs, Aurobindo supplies a variety of chemotherapeutics, including procarbazine. Their GMP-certified plants support global distribution, with regulatory approvals in multiple jurisdictions.

2. Contract Manufacturing Organizations (CMOs)

Given the complex synthesis and regulatory profile of procarbazine API, several CMOs offer manufacturing services:

• Cambrex Corporation (USA)
  Cambrex provides customized API synthesis, specializing in small- to medium-scale production of niche chemotherapeutics following GMP standards.

• LabQuest (India)
  Focused on complex APIs, LabQuest provides synthetic services to global clients, maintaining cGMP compliance and supplying APIs that meet stringent quality specifications.

• Catalent (USA/Europe)
  While primarily known for formulation, Catalent also offers API manufacturing services, including for chemotherapeutic drugs, leveraging their extensive GMP infrastructure.

---

Supply Chain and Regulatory Considerations

The dynamic landscape of pharmaceutical manufacturing has seen increased supplier diversification to mitigate risks associated with supply disruptions, especially post-pandemic. Companies sourcing procarbazine API must prioritize:

• GMP Certification
  Suppliers must maintain valid GMP compliance and undergo regular audits by regulators such as the FDA, EMA, or PMDA.

• Documentation and Validation
  Certificates of Analysis (COA), Stability Data, and validated manufacturing processes are crucial for regulatory submissions and batch consistency.

• Regional Regulatory Approvals
  Suppliers that possess approvals from major regulatory authorities facilitate faster market registration.

• Pricing and Lead Times
  Competitive pricing models are typically observed from Indian and Chinese manufacturers, with lead times varying according to order size and regulatory requirements.

---

Emerging Trends in API Sourcing

• Nearshoring and Regional Diversification
  Companies increasingly seek regional API sources to reduce supply chain vulnerabilities and align with regional regulatory requirements (e.g., EMA, FDA).

• Quality Standard Harmonization
  Suppliers conforming to multiple pharmacopeias (USP, EP, JP) enable broader market access for finished formulations.

• Technological Advancements
  Continuous process improvements and green chemistry practices are gaining prominence, enhancing API purity and reducing synthesis complexity.

---

Challenges and Future Outlook

Despite the availability of multiple API sources, challenges remain:

• Regulatory Stringency
  Increasing regulatory scrutiny necessitates comprehensive documentation and validation, with some suppliers facing delays in approval processes.

• Supply Chain Security
  Geopolitical factors and trade policies can impact availability, emphasizing the importance of supply diversification.

• CGMP Compliance Costs
  High costs associated with maintaining GMP facilities can influence pricing and availability.

Moving forward, the API sourcing landscape for procarbazine will likely evolve with greater emphasis on quality, regulatory compliance, and supply chain resilience.

---

Key Takeaways

• Multiple global manufacturers and CMOs produce high-quality procarbazine API, with significant players in North America, Europe, and Asia.
• Gaining access to GMP-certified API suppliers ensures compliance with regulatory standards and reduces manufacturing risks.
• Regional sourcing and diversified supply chains minimize disruptions and facilitate market expansion.
• Suppliers with regulatory approvals and comprehensive documentation streamline the path to registration.
• Industry trends favor green chemistry, process efficiencies, and regional manufacturing hubs to meet increasing demand for chemotherapeutic APIs.

---

FAQs

Q1. What are the primary regions supplying GMP-grade procarbazine API?
A1. North America, Europe, India, and China are the main regions with GMP-certified production facilities for procarbazine API.

Q2. How do I evaluate the quality of API suppliers for Gleostine?
A2. Assess their GMP certification, regulatory approvals, Certificates of Analysis, quality control protocols, and compliance with pharmacopeial standards such as USP, EP, or JP.

Q3. Are there cost advantages to sourcing procarbazine API from China or India?
A3. Yes, manufacturers in India and China often offer competitive pricing due to lower manufacturing costs, while maintaining quality standards through GMP compliance.

Q4. What role do CMOs play in the procarbazine API supply chain?
A4. CMOs provide customized manufacturing services, scaling production and offering flexibility, especially for small to medium batch sizes or specific formulation requirements.

Q5. How does regulatory compliance influence API sourcing decisions?
A5. Regulatory approvals and compliance streamline registration processes and reduce the risk of delays or rejections, making certified suppliers preferable for global markets.

---

References

[1] U.S. Pharmacopeia. Procarbazine hydrochloride monograph.
[2] European Pharmacopoeia. Monographs on chemotherapeutic APIs.
[3] Industry reports on global API manufacturing markets, 2022.
[4] GMP compliance guidelines by WHO and FDA.
[5] Recent trends in pharmaceutical supply chain resilience, PharmSource, 2022.